Last update 04 Nov 2024

Icotinib Hydrochloride

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Conmana, Icotinib, 埃克替尼
+ [5]
Mechanism
EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists), EGFR exon 21 L858R mutation inhibitors
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
CN (07 Jun 2011),
RegulationSpecial Review Project (CN), Priority Review (CN)
Login to view timeline

Structure

Molecular FormulaC22H22ClN3O4
InChIKeyPNNGXMJMUUJHAV-UHFFFAOYSA-N
CAS Registry1204313-51-8

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Non-Small Cell Lung Cancer
CN
07 Jun 2011
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Lung Cancer with Brain MetastasisPhase 3
CN
20 Jul 2018
EGFR-mutated non-small Cell Lung CancerPhase 3
CN
02 Jun 2015
EGFR Mutation Lung CancerPhase 3
CN
01 Sep 2014
EGFR positive non-small cell lung cancerPhase 3
CN
01 Sep 2014
Advanced Lung AdenocarcinomaPhase 3
CN
01 Dec 2012
EGFR positive Adenocarcinoma of LungPhase 3
CN
01 Dec 2012
Brain metastasesPhase 2-01 Dec 2018
Non-small cell lung cancer stage IIIBPhase 2
CN
09 May 2018
progressive non-small cell lung cancerPhase 2
CN
01 Jan 2018
PsoriasisPhase 2
CN
29 Nov 2017
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
NEWS
ManualManual
Phase 3
EGFR positive non-small cell lung cancer
EGFR L858R | EGFR Exon 19 Deletion
118
埃克替尼单药组
ttvcplymgz(qezdeuvyex) = wkdtrvdhsv uqedoxdadg (gywrnmtrci )
Positive
14 Oct 2024
埃克替尼联合TRT组
ttvcplymgz(qezdeuvyex) = gfeluuqgfj uqedoxdadg (gywrnmtrci )
Phase 2
EGFR positive Adenocarcinoma of Lung
Neoadjuvant
EGFR Mutation
133
Chemotherapy
qrtdhkcvtn(kojyheoxbm) = kgtgwlutdf nsdhztdkqe (iywzppamne )
Positive
09 Sep 2024
First-generation EGFR-TKIs
qrtdhkcvtn(kojyheoxbm) = nsdcdhocrw nsdhztdkqe (iywzppamne )
Phase 3
251
Icotinib 12 months
mknifmesgc(fkbknybboc) = kiwexordmb bmsvbsiirx (ifutvwvwqq, 43.3 - 80.3)
Positive
24 May 2024
Icotinib 6 months
mknifmesgc(fkbknybboc) = hnlzbxvplm bmsvbsiirx (ifutvwvwqq, 44.8 - 81.6)
WCLC2023
ManualManual
Phase 1/2
24
lfmjdxupfs(puunqqzqmy) = aumolertinib 110 mg po qd plus icotinib 125mg po tid pnnjpjrinz (vxbpwziqhq )
Positive
11 Sep 2023
Phase 2
109
qixwhlwxat(muibpyfrhh) = gfapubsrim aszwjjmdss (dpkqldbmku, 26.6 - 44.8)
Positive
20 Jun 2023
qixwhlwxat(muibpyfrhh) = ltysubrmlj aszwjjmdss (dpkqldbmku, 33.1 - 70.1)
Phase 2
128
hgegcelcut(iovwboiwao) = wulebitfyi ddmgjwxrhz (xkmuqemzgj, 91.3 - 99.9)
Positive
01 Mar 2023
(Observation)
hgegcelcut(iovwboiwao) = dlxdbndxwd ddmgjwxrhz (xkmuqemzgj, 75.1 - 92.9)
Not Applicable
105
downnbwrqz(brifukmrlm) = ehehiawlea jtiqxgvrej (sopqizsuyn )
-
03 Dec 2022
downnbwrqz(brifukmrlm) = uxuhzzxetk jtiqxgvrej (sopqizsuyn )
Phase 2
10
rpfqziwevd(txcwmebfzk) = -23.58% and -22.01% ijpklvfvox (hxmzsnzmol )
Positive
21 Oct 2022
Not Applicable
40
zqqpgogzll(fpjeqtlikq) = mbrrpyjdih dascntootn (igiwddzgam )
-
21 Sep 2022
Phase 2
116
ctlyqmchnf(gqkqnhhgzj) = pfacaotwoz yeoxtwnrdg (pjzwfjacfs, 43.1 - 61.9)
Positive
21 Jul 2022
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free